LeMaitre director exercises options, sells 5,044 shares

LEMAITRE VASCULAR director Bridget A. Ross reported an exercise-and-sale transaction in company stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LEMAITRE VASCULAR director Bridget A. Ross reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised stock options to acquire a total of 5,044 shares of Common Stock, including 1,600 shares at an exercise price of $47.19 per share and 3,444 shares at $48.60 per share.

On the same date, she completed an open‑market sale of 5,044 Common Stock shares at a weighted average price of $111.0956 per share, executed in multiple trades ranging from $111.00 to $111.30. Following these transactions, she directly owns 3,942 Common Stock shares, and the reported options tied to these exercises are fully vested and, after exercise, no longer outstanding.

Insider Trade Summary

Exercise and Sale: 5,044 shares ($317K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Ross Bridget A

Role Director

Sold 5,044 shs ($560K)

Approx. gross sale proceeds $560K

Approx. exercise cost $243K

Approx. pre-tax spread $317K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,444	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	1,600	$0.00	$0.00
Exercise	Common Stock	3,444	$48.60	$167K
Exercise	Common Stock	1,600	$47.19	$76K
Sale	Common Stock	5,044	$111.0956	$560K

Holdings After Transaction: Stock Option (Right to Buy) — 1,609 contracts (Direct); Common Stock — 3,942 shares (Direct)

Footnotes (3)

F1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
F2. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $111.00 to $111.30. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
F3. This option is fully vested and exercisable.

Key Figures

Shares sold: 5,044 shares Sale price: $111.0956/share Option exercise block 1: 1,600 shares at $47.19/share +4 more

7 metrics

Shares sold 5,044 shares Common Stock open-market sale on May 7, 2026

Sale price $111.0956/share Weighted average price; trades from $111.00 to $111.30

Option exercise block 1 1,600 shares at $47.19/share Stock option exercise into Common Stock

Option exercise block 2 3,444 shares at $48.60/share Stock option exercise into Common Stock

Shares owned after 3,942 shares Direct Common Stock ownership following transactions

Option expiration 1 December 12, 2027 Original expiration date for $47.19 options

Option expiration 2 December 11, 2026 Original expiration date for $48.60 options

Key Terms

open-market sale, Stock Option (Right to Buy), weighted average price, Exercise or conversion of derivative security

4 terms

open-market sale financial

"transaction_action: "open-market sale" for Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" in derivative entries"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bridget A. Ross report in her Form 4 for LEMAITRE VASCULAR (LMAT)?

Bridget A. Ross reported exercising stock options to acquire 5,044 LEMAITRE VASCULAR shares and then selling 5,044 shares in an open‑market transaction on May 7, 2026. The filing details both the option exercise prices and the sale’s weighted average price.

How many LEMAITRE VASCULAR (LMAT) shares did Bridget A. Ross sell and at what price?

Bridget A. Ross sold 5,044 shares of LEMAITRE VASCULAR Common Stock at a weighted average price of $111.0956 per share. The sale was executed in multiple trades ranging from $111.00 to $111.30, as disclosed in the Form 4 footnotes.

What option exercise prices did Bridget A. Ross disclose for LMAT shares?

Bridget A. Ross exercised options for 1,600 LEMAITRE VASCULAR shares at $47.19 per share and 3,444 shares at $48.60 per share. These exercises converted stock options into Common Stock, which was then involved in an open‑market sale the same day.

How many LEMAITRE VASCULAR (LMAT) shares does Bridget A. Ross own after the reported transactions?

After the reported May 7, 2026 transactions, Bridget A. Ross directly owns 3,942 shares of LEMAITRE VASCULAR Common Stock. This figure reflects her holdings following the option exercises and the open‑market sale of 5,044 shares disclosed in the Form 4.

Were Bridget A. Ross’s LMAT stock options vested at the time of exercise?

Yes. The Form 4 footnotes state that the reported stock options were fully vested and exercisable. Ross exercised options for 1,600 shares at a $47.19 strike price and 3,444 shares at a $48.60 strike price before the same‑day open‑market sale.

Did Bridget A. Ross use derivative securities in her LMAT Form 4 transactions?

Yes. She exercised Stock Option (Right to Buy) derivative securities covering 1,600 and 3,444 underlying LEMAITRE VASCULAR shares. These exercises converted options with strike prices of $47.19 and $48.60 into Common Stock, which was then sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/11/2026 - 05:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ross Bridget A

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2026		M		3,444⁽¹⁾	A	$48.6	7,386	D
Common Stock	05/07/2026		M		1,600⁽¹⁾	A	$47.19	8,986	D
Common Stock	05/07/2026		S		5,044	D	$111.0956⁽²⁾	3,942	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$48.6	05/07/2026		M			3,444	12/11/2021⁽³⁾	12/11/2026	Common Stock	3,444	$0	0	D
Stock Option (Right to Buy)	$47.19	05/07/2026		M			1,600	12/12/2022⁽³⁾	12/12/2027	Common Stock	1,600	$0	1,609	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $111.00 to $111.30. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

3. This option is fully vested and exercisable.

	/s/ Laurie A. Churchill, Attorney-in-fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR